A cCPE‐based xenon biosensor for magnetic resonance imaging of claudin‐expressing cells. Issue 1 (June 2017)

• Record Type: Journal Article
• Authors: Piontek, Anna; Witte, Christopher; May Rose, Honor; Eichner, Miriam; Protze, Jonas; Krause, Gerd; Piontek, Jörg; Schröder, Leif
• Other Names: Fromm Michael guestEditor.; Günzel Dorothee guestEditor.; Schulzke Jörg‐Dieter guestEditor.
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1397:Issue 1(2017)
• Page Start: 195
• Page End: 208
• Publication Date: 2017-06
• Subjects: Clostridium perfringens enterotoxin -- claudin -- tumor -- molecular resonance imaging -- xenon -- Hyper‐CEST; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.13363
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract : The majority of malignant tumors originate from epithelial cells, and many of them are characterized by an overexpression of claudins (Cldns) and their mislocalization out of tight junctions. We utilized the C‐terminal claudin‐binding domain of Clostridium perfringens enterotoxin (cCPE), with its high affinity to specific members of the claudin family, as the targeting unit for a claudin‐sensitive cancer biosensor. To overcome the poor sensitivity of conventional relaxivity‐based magnetic resonance imaging (MRI) contrast agents, we utilized the superior sensitivity of xenon Hyper‐CEST biosensors. We labeled cCPE for both xenon MRI and fluorescence detection. As one readout module, we employed a cryptophane (CrA) monoacid and, as the second, a fluorescein molecule. Both were conjugated separately to a biotin molecule via a polyethyleneglycol chemical spacer and later via avidin linked to GST–cCPE. Nontransfected HEK293 cells and HEK293 cells stably expressing Cldn4–FLAG were incubated with the cCPE‐based biosensor. Fluorescence‐based flow cytometry and xenon MRI demonstrated binding of the biosensor specifically to Cldn4‐expressing cells. This study provides proof of concept for the use of cCPE as a carrier for diagnostic contrast agents, a novel approach for potential detection of Cldn3/‐4–overexpressing tumors for noninvasive early cancer detection.